NeoGenomics Is Maintained at Neutral by B of A Securities

Dow JonesDec 14 00:08 · Ratings

BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $19

Futu NewsDec 13 21:31 · Ratings

NeoGenomics Study Highlights CtDNA's Potential To Predict Recurrence In High-Risk Melanoma; RaDaR Sequencing Assay Identifies Molecular Residual Disease Across Broader Patient Range, Enabling Earlier Detection And Prognosis Monitoring

BenzingaDec 11 21:08

NeoGenomics' Newly Published Study Underscores Potential of CtDNA as a Predictive Tool for Monitoring Patients With High-Risk Melanoma

BusinesswireDec 11 21:05

Strong Week for NeoGenomics (NASDAQ:NEO) Shareholders Doesn't Alleviate Pain of Three-year Loss

Simply Wall StDec 11 19:57

NeoGenomics Analyst Ratings

BenzingaDec 10 23:59 · Ratings